Dr. Herriot Tabuteau, a Haitian-born physician turned biotech entrepreneur, has been named to Forbes’ 2025 list of global billionaires after years of quietly building Axsome Therapeutics into a major player in treatments for central-nervous-system (CNS) disorders.

Forbes estimates his net worth at roughly $1.1 billion, a valuation largely tied to his ownership stake in Axsome and the company’s market rise following clinical and regulatory advances.

Tabuteau’s path to biotech prominence is unconventional. Born in Haiti in 1968 and raised in New York, he trained in the sciences — earning a bachelor’s degree in molecular biology and biochemistry from Wesleyan University and an M.D. from Yale School of Medicine — before moving into healthcare finance and later founding Axsome in January 2012. He remains the company’s founder, chief executive officer, president and chairman.

Axsome’s rise from start-up to publicly traded drug developer hinged on an aggressive in-house approach to neuroscience drug development and a string of clinical programs that caught investor attention. The company’s approved antidepressant Auvelity (for major depressive disorder) and its portfolio of CNS candidates helped transform Axsome’s valuation after years of modest market capitalisation. Recent late-stage trial results and regulatory filings, including work on treatments for Alzheimer’s-related agitation and promising data in narcolepsy programs, have cemented Axsome’s reputation as a specialist in hard-to-treat brain disorders.

Tabuteau is named on hundreds of patents tied to Axsome’s drug formulations and combination therapies, a signal of the company’s research intensity and his personal role in shaping its intellectual property strategy. Public patent records list him as an inventor on numerous grants related to combinations such as dextromethorphan-bupropion (central to some Axsome programs) and other proprietary pharmaceutical formulations.

Industry observers point to a few pivotal moments for Axsome that helped lift Tabuteau into the billionaire ranks. Auvelity’s FDA approval in 2022 and subsequent commercialisation accelerated revenues and investor confidence, while positive late-stage data for sleep-disorder and Alzheimer’s agitation candidates reinforced the company’s growth story. Axsome’s market cap and revenue trajectory in recent fiscal years made Tabuteau’s retained stake particularly valuable.

Tabuteau’s background in medicine, investment banking and hedge-fund experience equipped him with a rare mix of clinical understanding and capital markets savvy. Before founding Axsome, he worked in healthcare finance roles and managed investments in the life sciences sector, a blend that has informed Axsome’s tightly controlled cost structure and strategic decision to run many programs in-house rather than fully outsourcing trials. Analysts say that this approach both concentrates risk and can amplify returns when clinical readouts are successful.

Despite his public profile as a founder-CEO, Tabuteau has historically been media-shy, granting few interviews as Axsome navigated the long, expensive arc of drug development. Yet the company’s successes, and its potential pipeline across depression, Alzheimer’s, agitation, narcolepsy and related CNS indications, make Tabuteau a consequential figure in neuroscience therapeutics — and now, one of the very few Black billionaires created by pharma entrepreneurship.

As Axsome advances regulatory filings and commercial launches, Tabuteau and his company will face the familiar biotech challenges: converting promising clinical data into durable market share, managing competition from larger incumbents, and demonstrating long-term safety and efficacy. For now, his ascent from immigrant medical student to billionaire biotech founder highlights both the high stakes of drug development and the outsized rewards when science and execution align.